LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the completion of the sale of 833,333 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters of its previously announced public offering. The shares were sold at a price to the public of $4.50 per share for additional gross proceeds of approximately $3.75 million. After underwriting discounts and commissions and estimated offering expenses payable by Synta, net proceeds were approximately $3.5 million.
